The FDA announced on Sept. 12, 2025, that JB Chemicals and Pharmaceuticals Ltd is recalling Cetirizine Hydrochloride Tablets USP 10 mg due to tablets being imprinted with the wrong identification code. The recall affects 9,936 bottles distributed nationwide.
How to tell if you have it
- Brand: JB Chemicals
- Product: Cetirizine Hydrochloride Tablets USP 10 mg, 100 Tablets bottles
- Manufacturer: Unique Pharmaceuticals Labs (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.)
- Distributor: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816
- NDC: 16571-402-10
- Lot #: PY925014A
- Expiration: 1/31/2028
- Quantity: 9,936 bottles
The hazard
The tablets are imprinted with the wrong identification code. The FDA classified this as a Class III recall.
Context
GovInfoNow's records show JB Chemicals and Pharmaceuticals Ltd has two other recalls on record since April 23, 2026. On June 24, 2026, the brand recalled Cetirizine Tablets due to cross-contamination with Ranitidine. Other recent recalls of similar products include Unichem's Doxazosin 4mg Tablets recall (Jan. 21, 2026), American Regent's Levocarnitine Injection recall (April 16, 2026), and Synjardy XR Tablets recall (June 12, 2026).